Research Summary

Analyzed using Evidence Intelligence™

Higher semaglutide doses improve glucose control in type 2 diabetes

Key finding

Estimated treatment difference between 16 and 2 mg was -3.4 kg (-6.0 to -0.8; P = 0.011)

This study evaluated the effects of higher doses of semaglutide on glucose levels in type 2 diabetes patients, finding modest additional benefits at higher doses.

Evidence strength

Moderate confidence

Study type

RCTs

Follow-up

Short-Term (≤3 mo)

High bias

Last updated July 4, 2026

Quick read

Study at a glance

The essential study design details in one scan.

Population

Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes

Intervention

Semaglutide 2 mg

Study type

RCTs

Follow-up

Short-Term (≤3 mo)

Primary outcome

HbA1c

Comparator

Placebo

Plain-language summary

What this paper says

A plain-language read of the study's main message and where it applies.

Study focus

This study evaluated the effects of higher doses of semaglutide on glucose levels in type 2 diabetes patients, finding modest additional benefits at higher doses.

Clinical relevance

Understanding the effects of semaglutide at varying doses is crucial for optimizing diabetes management. While weight loss is beneficial for type 2 diabetes patients, the lack of significant improvement in glucose control at higher doses suggests that clinicians should consider individual patient responses when prescribing semaglutide.

Keep in mind

Specific results for several assessed outcomes were not reported. The study's findings may not be generalizable to all populations with type 2 diabetes. The sample size and demographic characteristics of participants were not detailed.

Published in

Journal Reference

Publication details and source links for this paper.

Vanita RA, Nils BJ, Bharath K, Ildiko L, Anne SL, John BB. Higher Semaglutide Doses Provide Modest Additional Glucose-Lowering Effect in Type 2 Diabetes. Diabetes Care. 2025;48(6):905-913. doi:10.2337/dc24-2425

View DOI View on PubMed View on PMC

Save this study and add notes to your research library.

Main Effects

Body weight decreased by an estimated 3.4 kg with the 16 mg dose compared to the 2 mg dose (P = 0.011).

No significant change in HbA1c levels was observed between the 16 mg and 2 mg doses (P = 0.245).

Treatment-emergent adverse events were more frequent in the higher dose groups.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Semaglutide and Adverse events incidence, Body weight, C-reactive protein, and 6 more.

This study contributes evidence to

Intervention

Semaglutide

Outcome

Adverse events incidence

Evidence topic

Adverse Events and Safety

Primary intervention

Semaglutide

Primary outcomes

Adverse events incidence
Body weight
C-reactive protein

Evidence topics

Adverse Events and Safety Weight Loss HbA1c Reduction Inflammatory and Vascular Markers

Primary intervention

Semaglutide

Primary outcomes

Adverse events incidence Body weight C-reactive protein

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 72

Why it is useful

Contributes to 9 evidence relationships
Includes primary outcome data
Linked to 5 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Semaglutide → Waist circumference

Evidence profile

NoneNo ChangeWeight & Anthropometrics

Unlock full evidence details

Unlock full evidence analysis

Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.

Evidence Suggest

Higher doses of semaglutide resulted in a 3.4 kg weight loss compared to lower doses.
No severe hypoglycemic episodes were reported during the trial.
HbA1c levels showed no significant difference between the highest and lowest doses.

Who this applies to

Adults with type 2 diabetes seeking weight management options.
Patients currently prescribed semaglutide or considering its use.

Keep in Mind

The study did not report specific results for several important health metrics.
Findings may not apply to all demographics or settings.
Further research is needed to explore long-term effects and safety of higher doses.

Between the Lines

Specific results for several assessed outcomes were not reported.
The study's findings may not be generalizable to all populations with type 2 diabetes.
The sample size and demographic characteristics of participants were not detailed.

Unlock Full Analysis

Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.

Already have an account?

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.

Related evidence relationships

Explore in Evidence Archive

This study contributes to the evidence on the following intervention-outcome relationships.

GLP-1 Receptor AgonistsHbA1c

Medications

11 studies

Detailed evidence

GLP-1 Receptor AgonistsBody Weight

Medications

10 studies

Detailed evidence

GLP-1 Receptor AgonistsBlood Pressure

Medications

2 studies

Detailed evidence

Included in these evidence collections

Curated evidence collections and hubs this study is part of.

GLP-1 Receptor Agonists Evidence Hub

All studies on GLP-1 Receptor Agonists

11 studies

intervention_hub

Contributes to GLP-1 Receptor Agonists evidence base.

HbA1c Evidence Hub

All studies measuring HbA1c

11 studies

outcome_hub

Measures HbA1c as a key outcome.

Body Weight Evidence Hub

All studies measuring Body Weight

10 studies

outcome_hub

Measures Body Weight as a key outcome.

Blood Pressure Evidence Hub

All studies measuring Blood Pressure

2 studies

outcome_hub

Measures Blood Pressure as a key outcome.

Recent Diabetes Research

Latest published studies

recency_collection

Published within the last 2 years.

Generated from the study's connected evidence using Evidence Intelligence™.

Does GLP-1 Receptor Agonists improve HbA1c?

Moderate Evidence

GLP-1 Receptor Agonists appears to improve HbA1c.

ConsensusScore™: Results are consistent across studies.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.8 | strong positive | ConsensusScore™ Consistent | 1 study

Why this answer: This answer is based on 24 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists affect body weight?

Emerging Evidence

GLP-1 Receptor Agonists may improve Body Weight.

ConsensusScore™: Results are consistent across studies.

Ranked evidence signals

1
Body weight
EvidenceScore™ Moderate | EvidenceScore™ 66.2 | moderate positive | ConsensusScore™ Consistent | 1 study

Why this answer: This answer is based on 23 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists improve blood pressure?

Emerging Evidence

Current evidence does not show a clear benefit of GLP-1 Receptor Agonists for Blood Pressure.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Diastolic blood pressure
EvidenceScore™ Limited | EvidenceScore™ 37.1 | neutral | ConsensusScore™ Mixed | 1 study
2
Systolic blood pressure
EvidenceScore™ Limited | EvidenceScore™ 37.1 | neutral | ConsensusScore™ Mixed | 1 study

Why this answer: This answer is based on 7 supporting studies and existing graph evidence signals.

Limitations

Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists improve body composition?

Emerging Evidence

GLP-1 Receptor Agonists may improve Body Composition.

ConsensusScore™: Results are consistent across studies.

Ranked evidence signals

1
Waist circumference
EvidenceScore™ Limited | EvidenceScore™ 30.4 | neutral | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on 5 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, archive views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Adverse Events and Safety Evidence Hub Weight Loss Evidence Hub HbA1c Reduction Evidence Hub Inflammatory and Vascular Markers Evidence Hub

Explore in archive

Open broader archive views for this relationship.

All studies on Semaglutide and HbA1c All studies on Semaglutide and Body weight All studies on Semaglutide and Adverse events incidence All studies on Semaglutide and Severe hypoglycemia

Related research

Read related research summaries.

Semaglutide may reduce cardiovascular events in non-diabetic patients.Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetes Oral semaglutide reduces cardiovascular events in type 2 diabetes Novel Semaglutide Injection Shows Non-Inferior Glycemic Control Oral semaglutide may improve cardiovascular event prevention in type 2 diabetes.

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.